[SaNOtize in Financial Express] Glenmark Pharmaceuticals and SaNOtize announce their Phase 3 Clinical Trials results on novel nasal spray for COVID-19

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment. Viral load wasreduced by 93.7% within 24 hours and by 99% within 48 hours of treatment with NONS, the company claimed.

Read more here.